OCX Logo

OncoCyte Corporation (OCX) 

NASDAQ
Market Cap
$37.12M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
45 of 960
Rank in Industry
36 of 550

Largest Insider Buys in Sector

OCX Stock Price History Chart

OCX Stock Performance

About OncoCyte Corporation

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a …

Insider Activity of OncoCyte Corporation

Over the last 12 months, insiders at OncoCyte Corporation have bought $11.19M and sold $0 worth of OncoCyte Corporation stock.

On average, over the past 5 years, insiders at OncoCyte Corporation have bought $13.16M and sold $5.21M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BROADWOOD PARTNERS, L.P. (10 percent owner) — $43.74M. Arno Andrew (director) — $199,998. James Andrea S. (Chief Financial Officer) — $145,800.

The last purchase of 20,000 shares for transaction amount of $45,800 was made by James Andrea S. (Chief Financial Officer) on 2024‑12‑05.

List of Insider Buy and Sell Transactions, OncoCyte Corporation

2024-12-05PurchaseChief Financial Officer
20,000
0.1168%
$2.29$45,800+3.91%
2024-10-02Purchase10 percent owner
1.32M
9.7663%
$2.95$3.88M-6.89%
2024-10-02PurchaseChief Financial Officer
33,670
0.2519%
$2.97$100,000-6.89%
2024-04-11Purchase10 percent owner
2.42M
28.8149%
$2.92$7.06M-3.37%
2024-04-11Purchasedirector
33,898
0.4083%
$2.95$99,999-3.37%
2024-04-11PurchaseCEO and President
3,390
0.0408%
$2.95$10,001-3.37%
2023-06-14Purchasedirector
30,000
0.0246%
$0.21$6,447-30.23%
2023-04-05Purchase10 percent owner
663,000
0.6681%
$0.30$200,027-37.96%
2023-04-03Purchase10 percent owner
26.83M
23.0078%
$0.30$8.09M-47.13%
2022-12-23Purchasedirector
250,000
0.2087%
$0.35$87,875-43.42%
2022-12-23Purchasedirector
75,000
0.0587%
$0.33$24,728-43.42%
2022-12-22Purchasedirector
25,000
0.0218%
$0.28$7,125-27.12%
2022-08-17Purchase
20,000
0.0168%
$0.87$17,400-58.47%
2022-08-17Purchase
7,500
0.0065%
$0.90$6,750-58.47%
2022-08-16PurchasePresident & CEO
40,000
0.0353%
$0.96$38,400-59.93%
2022-08-15Purchase
5,000
0.0042%
$0.97$4,850-61.86%
2022-08-15Purchase
115,523
0.0974%
$0.97$112,057-61.86%
2022-08-15Purchase
10,500
0.0087%
$0.95$9,975-61.86%
2022-08-15Purchase
10,000
0.0087%
$1.00$10,000-61.86%
2022-08-15Purchase
25,000
0.0202%
$0.93$23,250-61.86%

Insider Historical Profitability

<0.0001%
BROADWOOD PARTNERS, L.P.10 percent owner
6244405
37.0914%
$2.21130+2.24%
Arno Andrewdirector
69054
0.4102%
$2.2160<0.0001%
James Andrea S.Chief Financial Officer
53670
0.3188%
$2.2120
Riggs JoshCEO and President
3505
0.0208%
$2.2110
BROADWOOD CAPITAL INC
23353697
138.7195%
$2.2110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Broadwood Capital Inc$7.35M18.772.51M0%+$00.55
Awm Investment Company Inc$2.21M5.64754,2860%+$00.34
Pura Vida Investments LLC$1.54M3.92523,928-10.73%-$184,595.861.1
The Vanguard Group$726,267.001.86247,8730%+$0<0.0001
Morgan Stanley$361,008.000.92123,211+0.19%+$697.34<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.